

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting

March 9, 2023

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

She-Chia Jankowski, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Mark R. Conaway, PhD

Professor
Division of Translational Research and Applied
Statistics
Department of Public Health Sciences
University of Virginia
Charlottesville, Virginia

Jorge A. Garcia, MD, FACP

(Chairperson)
Chief, Division of Solid Tumor Oncology
George & Edith Richman Distinguished Scientist Chair
Professor of Medicine and Urology
GU Medical Oncology Program
University Hospitals Seidman Cancer Center
Case Comprehensive Cancer Center
Case Western Reserve University
Cleveland, Ohio

Ravi A. Madan, MD

Senior Clinician, Genitourinary Malignancies Branch
Head, Prostate Cancer Clinical Research Section
Program Director, Physician-Scientist Early
Investigator Program
Center for Cancer Research
National Cancer Institute, National Institutes of Health
Bethesda, Maryland

Anthony D. Sung, MD

Associate Professor of Medicine
Duke University School of Medicine
Duke Adult Blood and Marrow Transplant Clinic
Durham, North Carolina

Neil Vasan, MD, PhD

Assistant Professor
Division of Hematology & Oncology
Department of Medicine
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
New York, New York

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Jonathan D. Cheng, MD

(Industry Representative)
Head of Oncology Development
Global Drug Development
Bristol-Myers Squibb
Lawrenceville, New Jersey

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
March 9, 2023

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Christopher S. Coffey, PhD, MS

Christopher S. Coffey, PhD
Professor, Department of Biostatistics
Director, Clinical Trials Statistical & Data
Management Center
University of Iowa
Iowa City, Iowa

Louis F. Diehl, MD

Professor of Medicine
Duke University
Durham, North Carolina

Kieron M. Dunleavy, MD

Director of Hematology
Lombardi Comprehensive Cancer Center
Professor of Medicine
Georgetown University
Washington, District of Columbia

Sandra Finestone, PsyD

(Acting Consumer Representative)
Association of Cancer Patient Educators
Irvine, California

Paul V. Majkowski, Esq.

(Patient Representative)
Albertson, New York

Grzegorz (Greg) S. Nowakowski MD

Professor of Medicine and Oncology
Deputy Director for Clinical Research
Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota

Manjunath (Amit) Pai, PharmD, FCP

Professor and Chair
Department of Clinical Pharmacy
Co-Director of the PK Core
College of Pharmacy
University of Michigan, Ann Arbor
Ann Arbor, Michigan

Mikael A. Sekeres, MD, MS

Mikael A. Sekeres, M.D., M.S.
Professor of Medicine
Chief, Division of Hematology
Sylvester cancer Center
University of Miami
Miami, Florida

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
March 9, 2023

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence (OCE)
Director (Acting)
Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Marc R. Theoret, MD

Deputy Center Director, OCE
Supervisory Associate Director (Acting)
OOD, OND, CDER, FDA

Nicole Gormley, MD

Director
Division of Hematologic Malignancies II (DHM II)
OOD, OND, CDER, FDA

Yvette Kasamon, MD

Clinical Team Lead
DHM II, OOD, OND, CDER, FDA

Maryam Yazdy, MD

Clinical Reviewer
DHM II, OOD, OND, CDER, FDA